P/E ratio for Day One Biopharmaceuticals (DAWN)
P/E ratio as of July 2025 (TTM): -9.59
According to Day One Biopharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.59459. At the end of 2024 the company had a P/E ratio of -12.3.
P/E ratio history for Day One Biopharmaceuticals from 2021 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -12.3 | 100.21% |
| 2023 | -6.16 | -37.88% |
| 2022 | -9.92 | 175.51% |
| 2021 | -3.60 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.